• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Connect Biopharma Holdings Limited

    12/18/23 6:09:03 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTB alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001315082
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Connect Biopharma Holdings Ltd
    SEC File Number
    001-40212
    Address of Issuer
    12265 EL CAMINO REAL, SUITE 350
    SAN DIEGO
    CALIFORNIA
    92130
    Phone
    858-727-1040
    Name of Person for Whose Account the Securities are To Be Sold
    RA Capital Healthcare Fund LP
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    10% Stockholder

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    BTIG, LLC
    600 Montgomery Street
    6th Floor
    San Francisco � CA � 94111
    17657881666550.715507155912/18/2023
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock03/19/2021IPO InvestmentIssuerCheckbox not checked176578803/19/2021Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/21/2023355421556909.16
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/22/2023116311151902.17
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/27/20235246961672.06
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/29/20232377423902.38
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/30/2023250884254998.50
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/01/20233054732572.27
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/04/202344564583.89
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/05/20232569725697.00
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/06/20235582255822.00
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/07/20238711481242.52
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/08/20231285011857.98
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/11/20236173056236.03
    RA Capital Healthcare Fund LP
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/12/2023468351413132.42
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/21/20235950993244.65
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/22/20231947425433.04
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/27/2023878510325.89
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/28/202389669237.67
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/29/202339814002.50
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock11/30/20234200642694.90
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/01/202351155454.12
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/04/2023746767.41
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/05/202343034303.00
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/06/202393469346.00
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/07/20231458613602.90
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/08/202321511984.94
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/11/2023103359415.19
    RA Capital Nexus Fund, L.P.
    299 Berkeley Street
    18th Floor
    Boston � MA � 02116
    Common Stock12/12/20237841769171.64

    144: Remarks and Signature

    Remarks
    Date of Notice
    12/18/2023

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    RA Capital Healthcare Fund L.P., By: /s/ David Crowe, Director of Operations

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CNTB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNTB

    DatePrice TargetRatingAnalyst
    12/1/2025$9.00Buy
    Lake Street
    10/31/2025$10.00Buy
    BTIG Research
    6/12/2025$7.00Buy
    H.C. Wainwright
    3/4/2024$7.00Buy
    H.C. Wainwright
    More analyst ratings

    $CNTB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Connect Biopharma Holdings Limited

    SCHEDULE 13G - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/17/26 5:22:24 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Holdings Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    12/23/25 4:32:02 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Connect Biopharma Holdings Limited

    10-Q - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    11/12/25 9:04:30 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Connect Biopharma with a new price target

    Lake Street initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $9.00

    12/1/25 9:37:24 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Connect Biopharma with a new price target

    BTIG Research initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $10.00

    10/31/25 8:19:20 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Connect Biopharma with a new price target

    H.C. Wainwright initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $7.00

    6/12/25 7:54:22 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26th, 2026 at 2:40 p.m. ET. The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference. About Conn

    2/19/26 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight

    The atopic dermatitis market is expected to grow, driven by the extensive market penetration of approved therapies for moderate-to-severe atopic dermatitis and the entry of new therapies such as OX40 inhibitor (Rocatinlimab [KHK4083/AMG451]), OX40L inhibitor (Amlitelimab [KY1005]), PDE4 inhibitor (Orismilast), TSLP inhibitor (Bosakitug [BSI-045B]), IL-22RA1 blocker (Temtokibart [LP0145; LEO 138559]), IL-4Rα blocker (Rademikibart [CBP-201]), and others.LAS VEGAS, Feb. 16, 2026 /PRNewswire/ -- Recently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment practices, atopic dermatitis emerging drugs, market share of individual therapies,

    2/16/26 5:31:00 PM ET
    $ABBV
    $AMGN
    $APGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

    – Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to further confirm its unique ability to rapidly improve airway function with topline results expected in first quarter 2026 – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in mid-2026 – – Strong balance sheet with cash runway into 2027 through key clinical catalysts – SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Bio

    1/12/26 8:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Leadership Updates

    Live Leadership Updates

    View All

    Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

    – Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the size of its Board of Directors from six to seven directors and the appointment of Jim Schoeneck as a director effective today. "We are pleased to welcome Jim to our Board of Directors," sai

    7/22/25 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Attovia Therapeutics Appoints Chief Financial Officer

    FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ:CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory diseases. At Attovia, Mr. Chan will lead the company's finance and operations functions and serve on its Executive Committee, reporting to Tao Fu, Chief Executive Officer. "I am delighted to welcome Steve to Attovia at this critical growth period for the company. He brings over thirt

    10/15/24 7:30:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

    Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect's new management is currently evaluating the future clinical development strategy for rademikibartAs part of Connect's transformation into a U.S.-centric company, the Company will be significantly reducing its presence in ChinaCash and cash equivalents of $110.2 million expected to support planned operations into at least the first half of 2027 SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma," "Connect" or the "Company"), a U.S.-headquartered global clinical-stage bio

    9/5/24 4:05:00 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Financials

    Live finance-specific insights

    View All

    Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

    The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12The significant improvement in lung function was observed as early as Week 1 and was sustained through Week 24 with both doses of rademikibartSignificant improvement in asthma control occurred early and was sustained through Week 24 for both doses of rademikibartSafety results suggest rademikibart was generally well toleratedA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:

    12/12/23 6:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

    SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to d

    12/11/23 4:05:21 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

    Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose maintained both IGA 0/1 and EASI-75 through Week 52 Over 36 weeks of treatment in Stage 2 of the study, the percentage of patients achieving IGA 0/1 and EASI-75 continued to increaseRademikibart continued to be well tolerated over 52 weeks of treatmentA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings L

    11/21/23 6:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    7/1/24 4:16:48 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited (Amendment)

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/27/24 9:00:28 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited (Amendment)

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/27/24 4:19:26 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care